Blood and clotting factors in new AML patients on chemo
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how blood counts and clotting change in adults newly diagnosed with acute myeloid leukemia (AML) who receive a strong type of chemotherapy. It aims to better understand how to manage these patients during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have just been diagnosed with AML (but not the M3 subtype).
- You must be about to start a specific chemotherapy regimen with idarubicin and cytarabine at the doses listed.
- You cannot have received any chemotherapy for AML before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This study looks at how often a serious bowel problem (neutropenic enterocolitis) happens in adults with acute myeloid leukemia (AML) during intensive chemotherapy that lowers infection-fighting cells. The results may help doctors monitor and prevent complications during treatment.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This study looks at a new score (SiAML) to predict bleeding and blood clot risks in people newly diagnosed with acute leukemia. It aims to help doctors better manage these risks compared to current tests.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.